First batch development of hypertension drug
Two leading drug development companies are to manufacture the first batch of a drug candidate for hypertension, which is claimed to offer huge potential in controlling blood pressure in patients.
Two leading drug development companies are to manufacture the first batch of a drug candidate for hypertension, which is claimed to offer huge potential in controlling blood pressure in patients.
PCAS Pharma Synthesis - a supplier of intermediates and bulk actives - will prepare the first batch of Quantum Genomics Corp (QGC)'s lead molecule compound QCC001.
QGC - a New Jersey-based drug developer for metabolic and cardiovascular diseases - is expecting an initial cGMP batch of several kilograms of QGC001 from PCAS.
"PCAS has excellent technical skills and a solid reputation for providing quality services in manufacturing pharmaceutical active ingredients," said Lionel Segard, chairman and ceo of QGC. "One of QGC's strengths in development of innovative drugs that address significant unmet medical needs is our ability to select the relevant contracting partner to manage a study and to obtain the product on time and on budget."
Upon conclusion of the manufacturing phase, QGC will go through regulatory preclinical development, followed by Investigational Medicinal Product (IMPD) and Investigational New Drug (IND) Applications processes. QGC expects to start the first clinical trial of its hypertension resistant drug in humans by early 2009.
Cardiovascular diseases are one of the main causes of death in humans. The risk of myocardial infarction, stroke, kidney failure, heart failure or other complications doubles with every 20/10mmHg rise in blood pressure.
The market for hypertensive drugs is expected to double between 2005 and 2010.